Cargando…

Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer

Intrinsic and acquired resistance to anti-EGFR antibody therapy, frequently mediated by mutant or amplified KRAS oncogene, is a significant challenge in the treatment of colorectal cancer (CRC). However, the mechanism of KRAS-mediated therapeutic resistance is not well understood. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knickelbein, Kyle, Tong, Jingshan, Chen, Dongshi, Wang, Yi-Jun, Misale, Sandra, Bardelli, Alberto, Yu, Jian, Zhang, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195818/ https://www.ncbi.nlm.nih.gov/pubmed/29755130 http://dx.doi.org/10.1038/s41388-018-0289-x

Ejemplares similares

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2014)

PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors
por: Chen, Dongshi, et al.
Publicado: (2018)

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
por: Misale, Sandra, et al.
Publicado: (2015)

AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
por: Ye, Hua, et al.
Publicado: (2020)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells
por: Möller, Yvonne, et al.
Publicado: (2014)

Molecular Characterization of Acquired Resistance to KRAS(G12C)–EGFR Inhibition in Colorectal Cancer
por: Yaeger, Rona, et al.
Publicado: (2023)

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
por: Hofmann, Marco H., et al.
Publicado: (2022)

Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy
por: Yu, Shaorong, et al.
Publicado: (2013)

Puma (Puma concolor) epididymal sperm morphometry
por: Cucho, Hernán, et al.
Publicado: (2016)

Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death
por: Kuang, Chaoyuan, et al.
Publicado: (2022)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Multi‐population puma connectivity could restore genomic diversity to at‐risk coastal populations in California
por: Gustafson, Kyle D., et al.
Publicado: (2022)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma()
por: Zhou, Xiaoguang, et al.
Publicado: (2014)

Response of pumas (Puma concolor) to migration of their primary prey in Patagonia
por: Gelin, Maria L., et al.
Publicado: (2017)

A case of Anthrax in two captive pumas (Puma concolor)
por: EKEBAS, Gorkem, et al.
Publicado: (2018)

MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells
por: Lin, Lin, et al.
Publicado: (2018)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

Survival and Mortality of Pumas (Puma concolor) in a Fragmented, Urbanizing Landscape
por: Vickers, T. Winston, et al.
Publicado: (2015)

The Role of Scent Marking in Mate Selection by Female Pumas (Puma concolor)
por: Allen, Maximilian L., et al.
Publicado: (2015)

Diagnostic Uncertainty and the Epidemiology of Feline Foamy Virus in Pumas (Puma concolor)
por: Dannemiller, Nicholas G., et al.
Publicado: (2020)

Dietary patterns of a versatile large carnivore, the puma (Puma concolor)
por: Karandikar, Harshad, et al.
Publicado: (2022)

Using Species Distribution Models to Predict Potential Landscape Restoration Effects on Puma Conservation
por: Angelieri, Cintia Camila Silva, et al.
Publicado: (2016)

Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer
por: Hao, Suisui, et al.
Publicado: (2022)

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2018)

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
por: Chang, David Z, et al.
Publicado: (2009)

Lobo vs puma
Publicado: (2004)

Puma strikes Bax
por: Letai, Anthony
Publicado: (2009)

Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer
por: Song, Xiangping, et al.
Publicado: (2020)

Expression and clinical significance of ATM and PUMA gene in patients with colorectal cancer
por: Xiong, Hui, et al.
Publicado: (2017)

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation
por: Ohishi, Tomokazu, et al.
Publicado: (2020)

Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts
por: Lee, Hye Won, et al.
Publicado: (2019)

KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
por: Normanno, Nicola, et al.
Publicado: (2011)

Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2019)

Fractured Genetic Connectivity Threatens a Southern California Puma (Puma concolor) Population
por: Ernest, Holly B., et al.
Publicado: (2014)

Molecular evidence for a recent demographic expansion in the puma (Puma concolor) (Mammalia, Felidae)
por: Matte, Eunice M., et al.
Publicado: (2013)

Models of Regional Habitat Quality and Connectivity for Pumas (Puma concolor) in the Southwestern United States
por: Dickson, Brett G., et al.
Publicado: (2013)

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2009)

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_qka5obaqbdf37u132fi8fae6g3